158 related articles for article (PubMed ID: 37342994)
41. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.
Rigobello MP; Scutari G; Folda A; Bindoli A
Biochem Pharmacol; 2004 Feb; 67(4):689-96. PubMed ID: 14757168
[TBL] [Abstract][Full Text] [Related]
42. Progress in the characterization of gold drugs.
Grootveld MC; Razi MT; Sadler PJ
Clin Rheumatol; 1984 Mar; 3 Suppl 1():5-16. PubMed ID: 6432413
[TBL] [Abstract][Full Text] [Related]
43. NMR reveals the metabolic changes induced by auranofin in A2780 cancer cells: evidence for glutathione dysregulation.
Ghini V; Senzacqua T; Massai L; Gamberi T; Messori L; Turano P
Dalton Trans; 2021 May; 50(18):6349-6355. PubMed ID: 33885689
[TBL] [Abstract][Full Text] [Related]
44. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications.
Sannella AR; Casini A; Gabbiani C; Messori L; Bilia AR; Vincieri FF; Majori G; Severini C
FEBS Lett; 2008 Mar; 582(6):844-7. PubMed ID: 18294965
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Auranofin Loading within Ferritin Nanocages.
Lucignano R; Pratesi A; Imbimbo P; Monti DM; Picone D; Messori L; Ferraro G; Merlino A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430642
[TBL] [Abstract][Full Text] [Related]
46. The antioxidant 2,6-di-tert-butylphenol moiety attenuates the pro-oxidant properties of the auranofin analogue.
Shpakovsky DB; Shtil AA; Kharitonashvili EV; Tyurin VY; Antonenko TA; Nazarov AA; Osipova VP; Berberova NT; Foteeva LS; Schmidt C; Ott I; Milaeva ER
Metallomics; 2018 Mar; 10(3):406-413. PubMed ID: 29399682
[TBL] [Abstract][Full Text] [Related]
47. ESI MS studies highlight the selective interaction of Auranofin with protein free thiols.
Zoppi C; Messori L; Pratesi A
Dalton Trans; 2020 May; 49(18):5906-5913. PubMed ID: 32314767
[TBL] [Abstract][Full Text] [Related]
48. Characterization of the in vitro effect of triethylphosphine gold (auranofin) on human NK cell activity.
Pedersen BK; Abom B
Clin Exp Rheumatol; 1986; 4(3):249-53. PubMed ID: 3490341
[TBL] [Abstract][Full Text] [Related]
49. Broad Spectrum Functional Activity of Structurally Related Monoanionic Au(III) Bis(Dithiolene) Complexes.
Le Gal Y; Filatre-Furcate A; Lorcy D; Jeannin O; Roisnel T; Dorcet V; Fontinha D; Francisco D; Prudncio M; Martins M; Soeiro C; Sousa SA; Leitão JH; Morais TS; Bártolo I; Taveira N; Guerreiro JF; Marques F
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806151
[TBL] [Abstract][Full Text] [Related]
50. Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation.
Coffer MT; Shaw CF; Hormann AL; Mirabelli CK; Crooke ST
J Inorg Biochem; 1987 Jul; 30(3):177-87. PubMed ID: 3655788
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study.
Gunatilleke SS; de Oliveira CA; McCammon JA; Barrios AM
J Biol Inorg Chem; 2008 May; 13(4):555-61. PubMed ID: 18253767
[TBL] [Abstract][Full Text] [Related]
52. Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: A comparative study with auranofin and sunitinib.
Pavic A; Glišić BĐ; Vojnovic S; Warżajtis B; Savić ND; Antić M; Radenković S; Janjić GV; Nikodinovic-Runic J; Rychlewska U; Djuran MI
J Inorg Biochem; 2017 Sep; 174():156-168. PubMed ID: 28675847
[TBL] [Abstract][Full Text] [Related]
53. Gold(I) complexes with thiosemicarbazones: cytotoxicity against human tumor cell lines and inhibition of thioredoxin reductase activity.
Lessa JA; Guerra JC; de Miranda LF; Romeiro CF; Da Silva JG; Mendes IC; Speziali NL; Souza-Fagundes EM; Beraldo H
J Inorg Biochem; 2011 Dec; 105(12):1729-39. PubMed ID: 22005449
[TBL] [Abstract][Full Text] [Related]
54. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
55. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
56. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.
Park SH; Lee JH; Berek JS; Hu MC
Int J Oncol; 2014 Oct; 45(4):1691-8. PubMed ID: 25096914
[TBL] [Abstract][Full Text] [Related]
57. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
Schuh E; Pflüger C; Citta A; Folda A; Rigobello MP; Bindoli A; Casini A; Mohr F
J Med Chem; 2012 Jun; 55(11):5518-28. PubMed ID: 22621714
[TBL] [Abstract][Full Text] [Related]
58. Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite.
Shaw CF; Isab AA; Coffer MT; Mirabelli CK
Biochem Pharmacol; 1990 Sep; 40(6):1227-34. PubMed ID: 2403377
[TBL] [Abstract][Full Text] [Related]
59. Cytotoxic Activity of a Unique Monomeric Heterogeneous Two-Coordinate Ligand Monovalent Gold Complex with Tiopronin and a Heterocyclic Mercapto-Tetrazole Compound.
Sano N; Yoshino H; Sato Y; Honma H; Cordonier CEJ; Kashiwakura I
Curr Med Chem; 2022; 29(22):3973-3982. PubMed ID: 34666640
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
